Continuous subcutaneous insulin infusion in diabetes mellitus. A year's prospective trial

Insights

Continuous subcutaneous insulin infusion improved glycemic control in children with diabetes, despite some technical challenges. This method offers an acceptable way to manage diabetes in pediatric patients, enhancing their well-being.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders

Background:

  • Type 1 diabetes management in children requires effective strategies for glycemic control.
  • Conventional treatments often present challenges in achieving optimal blood glucose levels.

Purpose of the Study:

  • To compare continuous subcutaneous insulin infusion (CSII) with intensified conventional treatment (ICT) in pediatric patients.
  • To evaluate the efficacy and safety of CSII in improving glycemic control and well-being.

Main Methods:

  • A 12-month prospective trial involving 13 children (aged 8-16 years) comparing CSII and ICT.
  • Data collection included plasma glucose, M values, and glycosylated hemoglobin levels.

Main Results:

  • CSII group achieved significantly improved glycemic control (mean glucose 9.8 mmol/l, HbA1c 9.1%) compared to baseline and ICT group (mean glucose 15.5 mmol/l, HbA1c 10.4%).
  • Withdrawals occurred in both groups due to technical dissatisfaction; however, children on CSII reported improved well-being.
  • CSII group experienced increased diabetic ketoacidosis and subcutaneous abscesses, but no difference in serious hypoglycemia incidence.

Conclusions:

  • Continuous subcutaneous insulin infusion is an acceptable method for improving glycemic control in some children with diabetes.
  • While CSII shows promise, careful monitoring for potential complications like abscesses and ketoacidosis is necessary.

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...